Abstract | BACKGROUND: METHODS: The maximum D2 receptor density (Bmax ) and apomorphine (a D2 receptor agonist)-induced stereotypy were measured in rats orally dosed with vehicle, haloperidol (1 mg/kg), or brexpiprazole (4 or 30 mg/kg for Bmax , 6 or 30 mg/kg for stereotypy) for 21 days. Then, effects of oral administrations of brexpiprazole (3 mg/kg), aripiprazole (10 mg/kg), and olanzapine (3 mg/kg) against increases in apomorphine-induced hyperlocomotion and (±)-2,5-dimethoxy-4-iodoamphetamine hydrochloride (DOI: a 5-HT2A receptor agonist)-induced head twitches were evaluated in rats subcutaneously treated with risperidone (1.5 mg/kg/d) via minipumps for 21 days. RESULTS: CONCLUSION:
Brexpiprazole has a low risk of D2 receptor sensitization after a repeated administration and suppresses the rebound phenomena related to D2 and 5-HT2A receptors after a repeated administration of risperidone.
|
Authors | Naoki Amada, Hitomi Akazawa, Yuta Ohgi, Kenji Maeda, Haruhiko Sugino, Nobuyuki Kurahashi, Tetsuro Kikuchi, Takashi Futamura |
Journal | Neuropsychopharmacology reports
(Neuropsychopharmacol Rep)
Vol. 39
Issue 4
Pg. 279-288
(12 2019)
ISSN: 2574-173X [Electronic] United States |
PMID | 31487433
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2019 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of NeuropsychoPharmacology. |
Chemical References |
- Antipsychotic Agents
- Dopamine Agonists
- Quinolones
- Receptor, Serotonin, 5-HT2A
- Receptors, Dopamine D2
- Thiophenes
- brexpiprazole
- Haloperidol
- Apomorphine
|
Topics |
- Animals
- Antipsychotic Agents
(adverse effects, pharmacology)
- Apomorphine
(pharmacology)
- Dopamine Agonists
(pharmacology)
- Dyskinesia, Drug-Induced
(metabolism)
- Haloperidol
(pharmacology)
- Quinolones
(pharmacology)
- Rats
- Receptor, Serotonin, 5-HT2A
(metabolism)
- Receptors, Dopamine D2
(metabolism)
- Stereotyped Behavior
(drug effects)
- Thiophenes
(pharmacology)
|